<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192514</url>
  </required_header>
  <id_info>
    <org_study_id>31/17</org_study_id>
    <nct_id>NCT03192514</nct_id>
  </id_info>
  <brief_title>Electronic Deprescribing Tool for the Prevention of PIP</brief_title>
  <official_title>Electronic Deprescribing Tool for the Prevention of Potentially Inappropriate Prescribing for Older Patients: A Protocol for a Cluster Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Beira Interior</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Beira Interior</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a cluster randomized control trial aimed to measure the effectiveness of an
      educational knowledge transfer intervention to prescribers on the discontinuation of two
      targeted classes: Benzodiazepines andNon-benzodiazepine hypnotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators intend to develop an electronic decision support tool based on the best
      evidence available. This electronic deprescribing tool provides the rationale on the
      indications of prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine
      hypnotics and also provides interactive tapering suggestion integrated on a calendar. It is
      designed to help family doctors with the goal of improving health outcomes for the elderly.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of benzodiazepine and Non-benzodiazepine hypnotics consumption at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>The effectiveness of a new deprescribing electronic knowledge transfer tool for GP´s (rate of benzodiazepine and Non-benzodiazepine hypnotics discontinuation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of benzodiazepine and Non-benzodiazepine hypnotics consumption at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The effectiveness of a new deprescribing electronic knowledge transfer tool for GP´s (rate of benzodiazepine and Non-benzodiazepine hypnotics discontinuation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of benzodiazepine and Non-benzodiazepine hypnotics consumption at 12 months</measure>
    <time_frame>12 Months</time_frame>
    <description>The effectiveness of a new deprescribing electronic knowledge transfer tool for GP´s (rate of benzodiazepine and Non-benzodiazepine hypnotics discontinuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life of patients</measure>
    <time_frame>At baseline, 3 months, 6 months, 12 months</time_frame>
    <description>EQ-5D is a self-report questionnaire for measuring health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of falls of patients</measure>
    <time_frame>At baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Number of falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>motor vehicle crashes of patients</measure>
    <time_frame>At baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Accidents recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug withdrawal effects</measure>
    <time_frame>At baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Any clinical effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GPs level satisfaction regarding deprescribing</measure>
    <time_frame>At baseline, 12 months</time_frame>
    <description>Questionnaire with multiple choice, and open text format questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Beliefs about Medicines</measure>
    <time_frame>At baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Beliefs about Medicines Questionnaire (BMQ)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Prevention</condition>
  <condition>Benzodiazepine Dependence</condition>
  <arm_group>
    <arm_group_label>Electronic Deprescribing tool</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GPs of enrolled patients with access to the electronic Deprescribing tool</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care By GP´s</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Deprescribing tool</intervention_name>
    <description>Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.
The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.
The electronic Deprescribing tool is designed to support clinical decisions</description>
    <arm_group_label>Electronic Deprescribing tool</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients ≥65 years who have been taking Benzodiazepines or/and Non-benzodiazepine
             hypnotics for at least 3 months and who do not meet any exclusion criterion

        Exclusion Criteria:

          -  incapacity or unwillingness to provide written informed consent. Patient with
             dementia, psychotic disorder, a severe personality disorder; institutionalization;
             terminal illness, seizure disorders, rapid eye movement sleep disorders,
             benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder,
             epilepsy and periprocedural anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luis Monteiro, MD</last_name>
    <phone>275 329 002</phone>
    <email>d1012@ubi.pt</email>
  </overall_contact>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Beira Interior</investigator_affiliation>
    <investigator_full_name>Luís Miguel André Monteiro</investigator_full_name>
    <investigator_title>PhD Candidate at University of Beira Interior; Family Doctor</investigator_title>
  </responsible_party>
  <keyword>Polypharmacy</keyword>
  <keyword>Benzodiazepine use</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

